Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT01286012

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01286012
Other papers using this trial's data
  • Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients Kidney international, 2015-11 DOI, PubMed 26154926, PMC4653585 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01286012. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-03-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
Acronym
PRIME
Condition
End Stage Renal Disease
Intervention (Drug)
Soluble Ferric Pyrophosphate in liquid bicarbonate
Intervention (Drug)
Placebo: Conventional liquid bicarbonate
Intervention (Drug)
Erythrocyte Stimulating Agent (ESA)
Intervention (Drug)
Intravenous (IV) Iron
Lead sponsor
Rockwell Medical Technologies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01286012
Content hash
76bc461b3e37b408a1373fabd0f1091c68e620e63be0ec0215988cc7f1e8ffd5